Under construction – not a live service
Sign in
Taking peoplePhase 3

Testing AZD6234 for Adults With Type 2 Diabetes and Excess Weight

Tests AZD6234 against placebo in adults with type 2 diabetes and excess weight.

Plain-language title generated from the registry record
Registry title: A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Key facts

Where
A Coruña, Alzira (Valencia), Barcelona, Castilleja de La Cuesta, Sevilla, Ferrol (A Coruña), Lleida, Málaga, Oviedo, Segovia, and Seville, SpainSee the 10 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who also have overweight or obesity. It compares AZD6234 with placebo for weight change over 68 weeks.

Age
18 years or older
Sex
All sexes and gender identities can join.
Disease stage
Type 2 diabetes diagnosed at least 90 days before screening, with BMI of 27 kg/m2 or more and HbA1c between 6.0% (42 mmol/mol) and 10% (86 mmol/mol).
Earlier treatment
Diabetes managed with diet and exercise alone, or with a stable dose of an oral glucose-lowering medicine. Stable body weight (5% change or less) for at least 3 months. At least one self-reported unsuccessful attempt to lose weight. No GLP-1 medicine in the 3 months before randomisation. No insulin for type 2 diabetes in the 3 months before screening.
Biomarker or test result
HbA1c of 6.0% (42 mmol/mol) to 10% (86 mmol/mol) at screening.

Main reasons for not taking part

  • Obesity mainly caused by another hormone disorder
  • Type 1 diabetes or diabetes that is not clearly type 2
  • Ketoacidosis or hyperosmolar coma/state in the 3 months before screening
  • Significant liver or bile duct disease, or ALT or AST of 3.0 X ULN or more, or TBL above 1.5 X ULN
  • GLP-1 medicine in the 3 months before randomisation

Read by machine on 9 November 2026.

Where in Spain

  • A CoruñaHospital not named in the registryNot yet recruiting
  • Alzira (Valencia)Hospital not named in the registryNot yet recruiting
  • BarcelonaHospital not named in the registryNot yet recruiting
  • Castilleja de La Cuesta, SevillaHospital not named in the registryNot yet recruiting
  • Ferrol (A Coruña)Hospital not named in the registryNot yet recruiting
  • LleidaHospital not named in the registryNot yet recruiting
  • MálagaHospital not named in the registryNot yet recruiting
  • OviedoHospital not named in the registryNot yet recruiting
  • Segovia, Castille and LeónHospital not named in the registryNot yet recruiting
  • SevilleHospital not named in the registryNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
AstraZeneca
Trial code
NCT07784270
Record updated
28 October 2026
Original description
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatmentRead full original descriptionShow less

A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Inclusion: Males \& females (inclusive of all gender identities) age ≥18 years; BMI ≥27 kg/m2; Diagnosed with T2DM ≥90 days prior to Screening; HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling); Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation; History of at least one self-reported unsuccessful attempt to lose body weight in lifetime.

Exclusion: Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening; Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation; Use of insulin therapy for T2DM within 3 months prior to screening; Obesity primarily caused by other endocrine disorders; Significant hepatobiliary disease and/or any of the following results at Screening:; ALT ≥ 3.0 X ULN; AST ≥ 3.0 X ULN; TBL > 1.5 X ULN (except for cases of known Gilbert's Syndrome).

ClinicalTrials.gov NCT07784270